Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Expects EV ICD To Reduce ICD Complications, Costs

Executive Summary

The pivotal trial of Medtronic’s EV ICD, an implantable cardioverter defibrillator without a transvenous lead, has begun with implants in Illinois and New Zealand. The study will measure device-related complications with the device over six months and test EV ICD's ability to stop ventricular fibrillation.

You may also be interested in...

Medtronic’s Micra Transcatheter Pacemaker Improves Cardiac Function In MARVEL 2

New clinical trial results show accelerometer-based atrial sensing with an automated, enhanced algorithm delivered by Medtronic’s leadless ventricular pacemaker can significantly improve atrioventricular synchrony in patients with sinus rhythm and atrioventricular block.

Market Brief: Global Market For Implantable Defibrillators Will Reach $10Bn By 2023

The global market for implantable cardioverter defibrillators (ICDs) is expected to reach $10bn by 2023, a CAGR of 4.4%, driven by the rising prevalence of heart disease worldwide. This market is dominated by three players, Abbott, Boston Scientific and Medtronic, which continue to innovate. Cost of ICDs and surgical implantation remain barriers to wider adoption, but access to emerging markets is expected to drive sales.

UNTOUCHED Trial Shows Low Complication Rate With Boston Scientific’s Emblem S-ICD

Procedural outcome data of the UNTOUCHED trial of the Emblem subcutaneous implantable cardioverter defibrillator show low perioperative complication rates and high conversion efficacy of induced ventricular fibrillation in a high-risk patient population.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts